Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes

Hsin-Hung Chen 1,2,3,4,†, Shang-Yi Li 5,†, Weishan Chen 6,7 and Chia-Hung Kao 8,9,10,*

1 Institute of Medicine and Public Health, Chung Shan Medical University, Taichung 402, Taiwan; 605319@cch.org.tw
2 College of Nursing and Health Sciences, Dayeh University, Changhua 515, Taiwan
3 Division of Metabolism Endocrinology, Changhua Christian Hospital, Changhua 500, Taiwan
4 Division of Metabolism Endocrinology, Nantou Christian Hospital, Nantou 540, Taiwan
5 Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Changhua 500, Taiwan; 150614@cch.org.tw
6 Management Office for Health Data, China Medical University Hospital, Taichung 404, Taiwan; sandy8121985@gmail.com
7 College of Medicine, China Medical University, Taichung 404, Taiwan
8 Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 404, Taiwan
9 Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung 404, Taiwan
10 Department of Bioinformatics and Medical Engineering, Asia University, Taichung 413, Taiwan
* Correspondence: d10040@mail.cmuh.org.tw; Tel.: +886-4-2205-2121 (ext. 7412); Fax: +886-4-2233-6174
† These authors contributed equally to this work.

Received: 8 March 2019; Accepted: 9 April 2019; Published: 12 April 2019

Abstract: In this retrospective study, we attempted to evaluate the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and allergic rhinitis in patients with diabetes. We analyzed the Longitudinal Health Insurance Database 2000 subdatabase. Our study population included patients with type 2 diabetes (ICD-9-CM 250) between 2009 and 2012, and the study groups were DPP-4 inhibitor users and nonusers. Propensity scores were estimated in a multivariable logistic regression model for the analysis of allergic rhinitis (ICD-9-CM 477.9). Each group consisted of 6204 patients. DPP-4 inhibitor users had a reduced risk of allergic rhinitis (aHR = 0.74, 95% confidence interval (CI) = 0.61–0.90) in all stratifications. Among women, DPP-4 inhibitor users had a lower risk of allergic rhinitis (aHR = 0.67, 95% CI = 0.50–0.90). Among patients aged older than 40 years, DPP-4 inhibitor users had a decreased risk of allergic rhinitis (those aged 40–59: aHR = 0.75, 95% CI = 0.56–0.99; those aged ≥60: aHR = 0.73, 95% CI = 0.54–0.97). Among patients with comorbidities, the risk of allergic rhinitis for DPP-4 inhibitor users was 0.73 (95% CI = 0.60–0.90). High-dose (cumulative defined daily dose ≥648mg) DPP-4 inhibitor users had a decreased risk of allergic rhinitis (aHR = 0.23, 95% CI = 0.15–0.35). Our study revealed that Asian patients with diabetes who used DPP-4 inhibitors had decreased risk of allergic rhinitis, especially for DPP-4 inhibitor treatment in patients who were women, were older than 40 years, had higher diabetes severity scores, were taking higher doses of DPP-4 inhibitors, and had diabetes with comorbidities.

Keywords: dipeptidyl peptidase-4 (DPP-4) inhibitor; allergic rhinitis; diabetes

1. Introduction

A study showed that compared with patients without diabetes who had acute myocardial infarction (AMI), patients with diabetes have the same risk of suffering an AMI attack [1]. Other studies have shown
that patients with diabetes have a risk between 2-and 4-fold higher of developing cardiovascular disease, which may result in a more than 3-fold greater risk of mortality [2–4]. In 2011, diabetes mellitus (DM) was one of the critical non-communicable diseases emphasized by the World Health Organization (WHO), which has released numerous public health policies for DM control. DM is also a crucial public health problem in Taiwan and thus remains among the 10 leading causes of death. Many guidelines exist for medications used to treat DM. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a popular oral antidiabetic agent (OAD) [5]. Relevant studies have reported higher rates for adverse events such as nasopharyngitis, arthralgia, and headache related to DPP-4 inhibitor adverse events; however, regarding comparisons with other OADs, no findings have been statistically significant [6,7]. The DPP family has been observed in multiple organs and tissues, including some involved in the immune system, which could potentially lead to immune-modulating effects after taking DPP-4 inhibitors [8,9]. Prior to our research on DPP-4 inhibitors and allergic rhinitis (AR), we found a previous study talked about the effect of DPP-4 inhibitors on asthma control [10]. In the article, there were many mechanisms showed to explain the immunological pathways of DPP-4 inhibitors such as CD26, and it was also mentioned that there were many DPP-4 transcripts in the nasal epithelia of children who suffered from dust mite AR. AR is another prevalent disease worldwide, and many studies have mentioned that the major mechanism of AR is the stimulation of specific immunoglobulin E (IgE) [11,12]. Based on the immune mechanisms between AR and DPP-4 inhibitor, we hypothesized that some adverse events of nasopharyngitis caused by DPP-4 inhibitors may be related to AR attacks.

2. Methods

2.1. Data Source

Taiwan’s National Health Insurance program was established in 1995 and covers more than 99% of Taiwan’s population. In this study, we analyzed the Longitudinal Health Insurance Database 2000 subdatabase, from which we randomly selected 1 million patients listed in the National Health Insurance Research Database. Patient identification numbers were re-encoded when using the database to obtain patients’ demographic information, inpatient and outpatient records, medications, and treatments, while protecting their privacy. This study was approved by the Institutional Review Board of China Medical University as well as the Hospital Research Ethics Committee (IRB permit number: CMUH104-REC2-115-CR3).

2.2. Sampled Participants

Our study population included patients newly diagnosed with type II DM (ICD-9-CM 250) between 2009 and 2012; the study group comprised patients with DM who had received DPP-4 inhibitors, and the index date was the date of initial DPP-4 inhibitor therapy. We excluded patients who received DPP-4 inhibitors before being diagnosed with DM, had a history of AR (ICD-9-CM 477.9), or withdrew from the insurance program before the index date. The controls were randomly selected patients with DM who had never received DPP-4 inhibitor and were randomly assigned an index date between the date of DM diagnosis and December 31, 2012. The exclusion criteria for controls were the same as those for DPP-4 inhibitor users. Subsequently, the control group was one-fold size matched with the DPP-4 inhibitor group using propensity score matching. Furthermore, propensity scores were estimated in a multivariable logistic regression model with the following variables: DM diagnosis year, index year, gender, diabetes complications severity index (DCSI) score, and the comorbidities of coronary artery disease (CAD; ICD-9-CM 410–414), stroke (ICD-9-CM 430–438), hypertension (ICD-9-CM 401–405), hyperlipidemia (ICD-9-CM 272), and chronic kidney disease (CKD; ICD-9-CM 580–589). To evaluate the severity of DM, the DCSI score was based on diabetic complications. We also considered oral antidiabetic agents including thiazolidinedione, sulfonylureas, biguanides, and other antidiabetic drugs.
2.3. Events and Comorbidities

The event discussed in the present study was AR (ICD-9-CM 477.9). The end of the study was marked by the occurrence of AR, withdrawal from the insurance program, or the end of 2013. We considered CAD, stroke, hypertension, hyperlipidemia, and CKD to be risk factors for AR.

2.4. Statistical Analysis

Table 1 presents the demographic characteristics, DCSI scores, and comorbidities of DPP-4 inhibitor users and nonusers. We described the continuous variable of age using a mean and standard deviation and evaluated the difference between the two groups using the Wilcoxon rank-sum test. We presented the categorical variables as numbers and percentages and tested the differences between groups using chi-squared tests. Furthermore, the hazard ratios (HRs) and 95% confidence intervals (CIs) of the two groups were estimated using univariate and multivariate Cox proportional-hazards regression models. The variables in the multivariate model were gender, age, DCSI score, and comorbidities. Table 2 presents the HR of AR with the dosage of DPP-4 inhibitors. Moreover, we describe the DPP-4 inhibitor dosage using the cumulative defined daily dose (cDDD). According to the WHO, the cDDD is a unit of measurement for drugs and could help us to compute the doses of multiple drug types. Next, we divided DPP-4 inhibitor users into three groups by the first, second, and third tertiles of the cDDD. We used multiplicative analysis to evaluate the interaction effect of DPP-4 inhibitors and other oral antidiabetic agents on AR risk. Kaplan–Meier survival curves were used to describe the cumulative incidence of AR for the two groups, and the differences between the two groups were tested using a log rank test. The data analysis in this study was performed using SAS statistical software (Version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA); p < 0.05 was considered statistically significant.

Table 1. Baseline characteristics of diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors or not.

| Variable           | Diabetic Patients with DPP-4 inhibitors |                  |                  | p-Value * |
|--------------------|------------------------------------------|------------------|------------------|-----------|
|                    | Non-Users  | Users |                  |             |
|                    | (n = 6204) | (n = 6204) |                  |             |
| Gender             |            |       |                  |             |
| Female             | 2627 | 42.3 | 2663 | 42.9 | 0.51 |
| Male               | 3577 | 57.7 | 3541 | 57.1 |          |
| Age, years         |            |       |                  |             |
| 20–39              | 531 | 8.56 | 419 | 6.75 | 0.0002 |
| 40–59              | 2959 | 47.7 | 3103 | 50.0 |          |
| ≥60                | 2714 | 43.7 | 2682 | 43.2 |          |
| Mean (SD)          | 58.4 (13.5) | 58.6 (12.4) |                  | 0.60 a     |
| DCSI score         |            |       |                  |             |
| 0–1                | 2432 | 39.2 | 2373 | 38.2 | 0.39 |
| 2–3                | 2036 | 32.8 | 2031 | 32.7 |          |
| ≥4                 | 1736 | 28.0 | 1800 | 29.0 |          |
| Comorbidity        |            |       |                  |             |
| CAD                | 1934 | 31.2 | 1962 | 31.6 | 0.59 |
| Stroke             | 576 | 9.28 | 607 | 9.78 | 0.34 |
| Hypertension       | 4252 | 68.5 | 4314 | 69.5 | 0.23 |
| Hyperlipidemia     | 4279 | 69.0 | 4370 | 70.4 | 0.08 |
| CKD                | 917 | 14.8 | 918 | 14.8 | 0.98 |
| Medication         |            |       |                  |             |
| Thiazolidinedione  | 314 | 5.06 | 971 | 15.7 | <0.001 |
| Sulfonylureas      | 638 | 10.3 | 974 | 15.7 | <0.001 |
| Biguanides         | 902 | 14.5 | 1146 | 18.5 | <0.001 |
| Other antidiabetic drugs | 491 | 7.91 | 1425 | 23.0 | <0.001 |

*: chi-squared test; a: Wilcoxon’s rank-sum test. CAD: coronary artery disease; CKD: chronic kidney disease; DCSI score: diabetes complications severity index.
3. Results

Each group had 6204 patients with similar demographics; approximately 42% were women, and the mean age was 58.6 years (Table 1). Compared to the nonusers, the DPP-4 inhibitor users had a higher prevalence of other oral antidiabetic agents, including thiazolidinedione, sulfonylureas, biguanides, and other antidiabetic drugs (all $p$-values <0.001). The mean (range) follow-up period in DPP-4 inhibitor users and nonusers were 2.45 (0.01–4.86) and 2.37 (0.003–4.85) years, respectively.

The incidence rates of AR for DPP-4 inhibitor users and nonusers were 1.24 and 1.66 per 100 person-years, respectively. DPP-4 inhibitor users exhibited a reduced risk of AR (aHR = 0.81, 95% CI = 0.73–0.90) (Table 2), and DPP-4 inhibitor users had a lower incidence of AR, as evidenced in Figure 1. Next, we classified patients by gender, age, DCSI score, and comorbidities, and patients with any comorbidity were classified as the comorbidity group. Across all stratifications, we found that DPP-4 inhibitor users had a lower incidence rate of AR than did nonusers (among women: aHR = 0.74, 95% CI = 0.63–0.88; those aged 40–59 years: aHR = 0.83, 95% CI = 0.71–0.96; those aged ≥60 years: aHR = 0.78, 95% CI = 0.66–0.91; those with a DCSI score ≥4: aHR = 0.70, 95% CI = 0.57–0.85; and those with a comorbidity: aHR = 0.78, 95% CI = 0.70–0.87).

![Figure 1](image-url)  
*Figure 1.* The incidence rates of allergic rhinitis (AR) for DPP-4 inhibitor users and nonusers were 1.24 and 1.66 per 100 person-years, respectively. DPP-4 inhibitor users exhibited a reduced risk of AR (aHR = 0.74, 95% confidence interval (CI) = 0.61–0.90), and DPP-4 users had a lower incidence of AR.

Subsequently, we discussed the dose of DPP-4 inhibitors, the values for which are presented in Table 3. Compared with nonusers, low-dose (cDDD ≤279 mg) DPP-4 inhibitor users had a 1.87-fold higher risk of AR (95% CI = 1.65–2.11), medium-dose (280 ≤ cDDD ≤ 647 mg) DPP-4 inhibitor users had a lower risk of AR (aHR = 0.75, 95% CI = 0.64–0.88), and high-dose (cDDD ≥ 648 mg) DPP-4 inhibitor users had a lower risk of AR (aHR = 0.25, 95% CI = 0.20–0.31).
Table 2. Incidence rate and hazard ratio of allergic rhinitis in diabetes patients of DPP-4 inhibitor users compared to non-users.

| Variable                  | Diabetic Patients with DPP-4 inhibitors | Compared to Non-User |
|---------------------------|----------------------------------------|---------------------|
|                           | Non-Users | Users | Crude | Adjusted |
|                           | Event PY IR Event PY IR HR (95% CI) p-Value HR (95% CI) p-Value |
| Overall                   | 245 14,725 1.66 188 15,219 1.24 0.75 (0.62, 0.91) 0.003 0.81 (0.73, 0.90) 0.001 |
| Gender                    |           |       |       |          |
| Female                    | 111 6308 1.76 77 6659 1.16 0.67 (0.50, 0.90) 0.008 0.74 (0.63, 0.88) 0.004 |
| Male                      | 134 8417 1.59 111 8560 1.30 0.81 (0.63, 1.05) 0.11 0.87 (0.75, 1.00) 0.05 |
| Age                       |           |       |       |          |
| 20–39                     | 29 1280 2.27 21 1061 1.98 0.86 (0.49, 1.51) 0.60 0.84 (0.56, 1.26) 0.39 |
| 40–59                     | 111 7283 1.52 88 7898 1.11 0.75 (0.56, 0.99) 0.045 0.83 (0.71, 0.96) 0.01 |
| ≧60                       | 105 6163 1.70 79 6260 1.26 0.74 (0.55, 0.96) 0.047 0.79 (0.66, 0.93) 0.02 |
| DCDSI score               |           |       |       |          |
| 0–1                       | 90 5866 1.53 73 5799 1.26 0.83 (0.61, 1.14) 0.24 1.02 (0.86, 1.21) 0.85 |
| 2–3                       | 74 4931 1.50 56 5110 1.10 0.74 (0.52, 1.05) 0.09 0.78 (0.65, 0.94) 0.01 |
| ≧4                        | 81 3928 2.06 59 4310 1.37 0.67 (0.48, 0.94) 0.02 0.70 (0.57, 0.85) 0.02 |
| Comorbidity†              |           |       |       |          |
| Yes                       | 219 13,065 1.68 168 13700 1.23 0.74 (0.61, 0.91) 0.004 0.78 (0.70, 0.87) 0.001 |
| No                        | 26 1660 1.57 20 1519 1.32 0.79 (0.44, 1.42) 0.43 0.81 (0.56, 1.36) 0.24 |

PY, person-years; IR, incidence rate, per 100 person-years; HR, hazard ratio; † Patients with any one of comorbidity were classified as the comorbidity group; CI, confidence interval; Models adjusted by gender, age, DCDSI score, and all comorbidities and medications are listed in Table 1.

Table 3. Incidence rate and hazard ratio of allergic rhinitis in diabetes patients by cumulative dose of DPP-4 inhibitor use compared to non-users.

| Variable                  | Crude | Adjusted |
|---------------------------|-------|----------|
|                           | HR (95% CI) p-Value | HR (95% CI) p-Value |
| Non-users                 | 1.0   | 1.0      |
| DPP-4 inhibitor use, cDDDs |       |          |
| ≦279                      | 2046 112 4097 2.73 1.64 (1.31, 2.05) <0.0001 1.87 (1.65, 2.11) <0.0001 |
| 280–647                   | 2073 50 4373 1.14 0.68 (0.50, 0.93) 0.01 0.75 (0.64, 0.88) 0.01 |
| ≧648                      | 2085 26 6749 0.39 0.24 (0.16, 0.35) <0.0001 0.25 (0.20, 0.31) <0.0001 |

PY, person-years; IR, incidence rate, per 100 person-years; Models adjusted by gender, age, DCDSI score, and all comorbidities and medications listed in Table 1. HR, hazard ratio; CI, confidence interval; cDDD, cumulative defined daily dose.

We observed statistically significant lower risk for patients with both DPP-4 inhibitors and Thiazolidinedione (aHR = 0.69, 95% CI = 0.56–0.85), both with DPP-4 inhibitors and sulfonylureas (aHR = 0.76, 95% CI = 0.59–0.99) or both with DPP-4 inhibitors and other antidiabetic drugs (aHR = 0.63, 95% CI = 0.52–0.76) than those without DPP-4 inhibitors, thiazolidinedione, sulfonylureas, and other antidiabetic drugs (Table 4).

Table 4. Cox proportional hazard regression analysis for the interaction of other oral antidiabetic agents and DPP-4 inhibitors on allergic rhinitis risk.

| Variables                  | Adjusted HR(95% CI) p-Value |
|---------------------------|-----------------------------|
| DPP-4 inhibitors          | Thiazolidinedione            |
| No                        | 5890 240 1 (Reference)      |
| Yes                       | 5233 158 0.76 (0.69, 0.85)  |
| No                        | 314 5 0.32 (0.20, 0.52)     |
| Yes                       | 971 30 0.69 (0.56, 0.85)    |
| DPP-4 inhibitors          | Sulfonylureas                |
| No                        | 5566 228 1 (Reference)      |
| Yes                       | 5230 165 0.79 (0.71, 0.88)  |
| No                        | 638 17 0.75 (0.57, 0.99)    |
| Yes                       | 974 23 0.76 (0.59, 0.99)    |

DPP-4 inhibitors, Thiazolidinedione, Sulfonylureas; p-Value ≤ 0.05.
Table 4. Cont.

| Variables                      | N   | Event | Adjusted HR (95% CI) | p-Value * & |
|-------------------------------|-----|-------|----------------------|-------------|
| DPP-4 inhibitors             |     |       |                      |             |
| No                           | No  | 5302  | 227                  | 1 (Reference) |
| Yes                          | No  | 5058  | 155                  | 0.73 (0.65, 0.82) |
| No                           | Yes | 902   | 18                   | 0.53 (0.40, 0.69) |
| Yes                          | Yes | 1146  | 33                   | 0.90 (0.72, 1.14) |
| DPP-4 inhibitors             |     |       |                      | 0.002       |
| No                           | No  | 5713  | 234                  | 1 (Reference) |
| Yes                          | No  | 4779  | 150                  | 0.77 (0.70, 0.86) |
| No                           | Yes | 491   | 11                   | 0.47 (0.34, 0.65) |
| Yes                          | Yes | 1425  | 38                   | 0.63 (0.52, 0.76) |

Models adjusted by gender, age, DCSI score, and all comorbidities and medications listed in Table 1. *p-value for interaction.

4. Discussion

4.1. DM and AR

In terms of quality of life, the effect of AR on patients is obvious. In the United States, the cost of AR treatment is estimated to be more than US$6 billion per year [13,14]. One of the key methods for managing AR is to reduce exposure to sensitizing allergens [15,16]. Avoiding possible allergens can decrease specific immunoglobulin E (IgE)-mediated reactions, which are driven by type 2 helper T (Th2) cells. The chain reaction of AR could cause eosinophils and basophils aggregation at the same time as mucosal inflammation [11,12]. IgE induced the reaction of T-cells, B-cells, and mast cells, which resulted in more cytokine (such as interleukin (IL)-4 and IL-18) stimulation in patients with AR [17]. DM with insulin resistance (IR) altered lipid homeostasis and cytokines. IR might result in higher levels of inflammatory markers, such as C-reactive protein and IL-6, because of increased systemic inflammation [18]. A study showed that DM was associated with allergic states [19]. Through modified innate immunity, patients with DM had a higher incidence of impaired endothelial function and higher rate of coagulopathy dysfunction caused by a prothrombotic condition [20,21]. Compared with other Asian studies [22,23], type 2 DM was not a substantial risk factor for AR. For example, DM with comorbidities was not a risk factor for AR in a Korean study, and rheumatic arthritis was a risk factor for AR in a Taiwanese study. In the present study, patients with diabetes and DPP-4 inhibitors had a lower incidence rate of AR. Patients with diabetes with comorbidities such as cardiovascular disease, stroke, or hypertension had lower AR incidence rates in the DPP-4 inhibitor group. Lower AR incidence rates were noted in our female patients with DM who used DPP-4 inhibitors. The severity of DM is a factor for AR attacks, but a lower AR incidence rate was noted in the DPP-4 inhibitor group. Overall, our study showed that DPP-4 inhibitors might play a role in decreased AR incidence rates.

4.2. DPP-4 Inhibitor Immunity and AR

In our analysis, higher cDDDs of DPP-4 inhibitors could decrease AR. A possible explanation is that a higher dose of DPP-4 inhibitors could alter the immune response of patients with DM. Studies have mentioned the relationship between DPP-4 inhibitors and infection [7,24], asthma [25], and lung injury [26]. Cluster of differentiation (CD) 26 might play a crucial role between DPP-4 inhibitors and immune regulation [27,28]. Higher levels of CD26 were equal to strongly activated T-cells and might cause potential immune-modulating effects in patients with DM [8]. However, DPP-4 inhibitors belong to the DPP-4 family, and some studies have shown that DPP-4 inhibitors could affect DPP-8 and DPP-9 reactions and thereby induce more immune-modulating effects [9]. In one in vitro study, DPP-4 inhibitor could modify T-cell function and decrease the production of inflammatory cytokines [29]. Activated T-cells were also noted in the pathway of the AR mechanism induced by IgE cells [17]. Higher doses of DPP-4 inhibitor (>280 cDDD) could alter the T-cell pathway to improve the
IgE response in AR. To confirm this, more detailed basic animal or cell studies could be designed and conducted in the future.

5. Limitations

This study had some limitations. First, in our database, we could not determine all other potential confounding factors, including patients’ nutritional states, smoking or alcohol consumption, and environmental factors such as particular matter (PM2.5). Second, our study group only included type 2 DM because DPP-4 inhibitors are prescribed to patients with this disease in Taiwan. Finally, AR diagnoses were only collected according to ICD9 codes and without any confirmation from other specialists.

6. Conclusions

Few studies have discussed the association between DPP-4 inhibitors and AR. Our study revealed that Taiwanese patients with DM who used DPP-4 inhibitors exhibited decreased incidence rates of AR, especially in the cases of DPP-4 inhibitor treatment in women, patients older than 40 years, those with higher DCSI scores, and those with DM and comorbidities.

Author Contributions: All authors have contributed substantially and are in agreement with the content of the manuscript. Conception/Design: H.-H.C., S.-Y.L., C.-H.K.; Provision of study materials: C.-H.K.; Collection and/or assembly of data: All authors; Data analysis and interpretation: All authors; Manuscript preparation: All authors; Final approval of manuscript: All authors. The guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to the published article, is C.-H.K.

Funding: This research received no external funding.

Acknowledgments: This work was supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW108-TDU-B-212-133004); the China Medical University Hospital (DMR-107–192, CMU107-ASIA-19); the Academia Sinica Stroke Biosignature Project (BM10701010021); the MOST Clinical Trial Consortium for Stroke (MOST 107–2321-B-039–004-); the Tseng-Lien Lin Foundation, Taichung, Taiwan; and the Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Conflicts of Interest: All authors report no conflicts of interest.

References

1. Haﬀner, S.M.; Lehto, S.; Rønnemaa, T.; Pyörräälä, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998, 339, 229–234. [CrossRef]
2. Preis, S.R.; Hwang, S.J.; Coady, S.; Pencina, M.J.; D’Agostino, R.B.S.; Savage, P.J.; Levy, D.; Fox, C.S. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119, 1728–1735. [CrossRef] [PubMed]
3. Malmberg, K.; Yusuf, S.; Gerstein, H.C.; Brown, J.; Zhao, F.; Hunt, D.; Piegas, L.; Calvin, J.; Keltai, M.; Budaj, A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000, 102, 1014–1019. [CrossRef]
4. Donahoe, S.M.; Stewart, G.C.; McCabe, C.H.; Mohanavelu, S.; Murphy, S.A.; Cannon, C.P.; Antman, E.M. Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298, 765–775. [CrossRef]
5. Riddle, M.C.; Bakris, G.; Blonde, L.; Boulton, A.J.M.; D’Alessio, D.; Greene, E.L. Standards of Medical Care in Diabetes-2019. Diabetes Care 2019, 42 (Suppl. 1), s1–s83.
6. Stein, S.A.; Lamos, E.M.; Davis, S.N. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin. Drug Saf. 2013, 12, 153–175. [CrossRef]
7. Amori, R.E.; Lau, J.; Pittas, A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007, 298, 194–206. [CrossRef] [PubMed]
8. De Meester, I.; Korom, S.; Van Damme, J.; Scharpé, S. CD26, let it cut or cut it down. Immunol. Today. 1999, 20, 367–375. [CrossRef]
9. Lankas, G.R.; Leiting, B.; Roy, R.S.; Eiermann, G.J.; Beconi, M.G.; Bišču, T.; Chan, C.C.; Edmondson, S.; Feeney, W.P.; He, H. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. *Diabetes* **2005**, *54*, 2988–2994. [CrossRef]

10. Colice, G.; Price, D.; Gerhardsson de Verdier, M.; Rabon-Stith, K.; Ambrose, C.; Cappell, K.; Irwin, D.E.; Juneau, P.; Vlahiotis, A. The effect of DPP-4 inhibitors on asthma control: An administrative database study to evaluate a potential pathophysiologic relationship. *Pragmat. Obs. Res.* **2017**, *8*, 231–240. [CrossRef]

11. Wheatley, L.M.; Togias, A. Clinical practice. Allergic rhinitis. *N. Engl. J. Med.* **2015**, *372*, 456–463. [CrossRef]

12. Wallace, D.V.; Dykewicz, M.S.; Bernstein, D.I.; Blessing-Moore, J.; Cox, L.; Khan, D.A. The diagnosis and management of rhinitis: An updated practice parameter. *J. Allergy Clin. Immunol.* **2008**, *122*, S1–S84. [CrossRef]

13. Hashimoto, Y.; Futamura, A. Prevalence of allergic rhinitis is lower in subjects with higher levels of fasting plasma glucose. *Allergy Asthma Proc.* **2010**, *31*, 99–103. [CrossRef]

14. Thompson, A.K.; Juniper, E.; Meltzer, E.O. Quality of life in patients with allergic rhinitis. *Ann. Allergy Asthma Immunol.* **2000**, *85*, 338–347. [CrossRef]

15. Plattis-Mills, T.A. Allergen avoidance. *J. Allergy Clin. Immunol.* **2004**, *113*, 388–391. [CrossRef]

16. Wallace, D.V.; Dykewicz, M.S.; Bernstein, D.I.; Blessing-Moore, J.; Cox, L.; Khan, D.A. The diagnosis and management of rhinitis: An updated practice parameter. *J. Allergy Clin. Immunol.* **2008**, *122*, S1–S84. [CrossRef]

17. Janeway, C.A., Jr.; Travers, P.; Walport, M.; Shlomchik, M.J. *The Immune System in Health and Disease*. 16th ed.; Garland Science: New York, NY, USA, 2001.

18. Esposito, K.; Nappo, F.; Marfella, R.; Giugliano, G.; Giugliano, F.; Ciotola, M. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation* **2002**, *106*, 2067–2072. [CrossRef]

19. Hashimoto, Y.; Futamura, A. Prevalence of allergic rhinitis is lower in subjects with higher levels of fasting plasma glucose. *Diabetes Care* **2010**, *33*, e143. [CrossRef]

20. Meigs, J.B.; Hu, F.B.; Rifai, N.; Manson, J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. *JAMA* **2004**, *291*, 1978–1986. [CrossRef]

21. Goldberg, R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. *J. Clin. Endocrinol. Metab.* **2009**, *94*, 3171–3182. [CrossRef]

22. An, S.Y.; Choi, H.G.; Kim, S.W.; Park, B.; Lee, J.S.; Jang, J.H. Analysis of various risk factors predisposing subjects to allergic rhinitis. *Asian Pac. J. Allergy Immunol.* **2015**, *33*, 1431–1451. [CrossRef]

23. Lai, N.S.; Tsai, T.Y.; Koo, M.; Lu, M.C. Association of rheumatoid arthritis with allergic diseases: A nationwide population-based cohort study. *Allergy Asthma Proc.* **2015**, *36*, 99–103. [CrossRef]

24. Richter, B.; Bandeira-Echtler, E.; Bergerhoff, K.; Lerch, C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. *Vasc. Health Risk Manag.* **2008**, *4*, 753–768. [CrossRef]

25. Stephan, M.; Suhling, H.; Schade, J.; Wittlake, M.; Tasic, T.; Klemann, C.; Pabst, R.; Jurawitz, M.C.; Raber, K.A.; Hoymann, H.G.; et al. Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: A matter of dose, route, and time. *Physiol. Rep.* **2013**, *1*, e0009. [CrossRef]

26. Kawasaki, T.; Chen, W.; Htwe, Y.M.; Tatsumi, K.; Dudek, S.M. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2018**, *315*, L834–L845. [CrossRef]

27. Nieto-Fontarigo, J.J.; González-Barcala, F.J.; San-José, M.E.; Cruz, M.J.; Linares, T.; Soto-Mera, M.T.; Valdés-Cuadrado, L.; García-González, M.A.; Andrade-Bulos, L.J.; Arias, P.; et al. Expansion of a CD26low Efector TH Subset and Reduction in Circulating Levels of sCD26 in Stable Allergic Asthma in Adults. *J. Investig. Allergol. Clin. Immunol.* **2018**, *28*, 113–125. [CrossRef]

28. Nieto-Fontarigo, J.J.; González-Barcala, F.J.; San José, E.; Arias, P.; Nogueira, M.; Salgado, F.J. CD26 and asthma: A comprehensive review. *Clin. Rev. Allergy Immunol.* **2016**, *56*, 139–160. [CrossRef]

29. Aytac, U.; Dang, N.H. CD26/dipeptidyl peptidase IV: A regulator of immune function and a potential molecular target for therapy. *Curr. Drug Targets Immune Endocr. Metabol. Disord.* **2004**, *4*, 11–18. [CrossRef]